New plavix rival enters human testing
NCT ID NCT07619885
First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This early-stage trial compares a new investigational drug, CG-0255, to the established blood thinner Plavix in 136 healthy adults aged 18-55. The goal is to see if CG-0255 is processed by the body similarly to Plavix and has the same effect on preventing blood clots. Participants will receive either CG-0255 or Plavix, and researchers will measure drug levels and platelet function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CG-0255 (a prodrug similar to clopidogrel/Plavix)
What this could lead to
If successful, this could lead to a new option for preventing dangerous blood clots in people with heart disease or stroke risk.
What could go wrong
This is a very early Phase 1 study in healthy volunteers, not patients. It only measures drug levels and platelet activity, not actual clinical outcomes like heart attacks. Many drugs fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Syneos Health
RECRUITINGMiami, Florida, 33101, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••